March 26, 2014

Page 1

University

Sports

LISKER TO TAKE LEGACY TO SMITH

DAVIDSON TOPS DUKE BASEBALL PAGE 5

PAGE 2

The chronicle T H E I N D E P E N D E N T D A I LY AT D U K E U N I V E R S I T Y

XXXXXDAY, MMMM WEDNESDAY, MARCHXX, 26,2013 2014

New guidelines recommend the use of statins

WWW.DUKECHRONICLE.COM

ONE ONEHUNDRED HUNDREDAND ANDEIGHTH NINTH YEAR, YEAR, ISSUE ISSUE XXX 102

Veteran student enrollment surges over years

by Gautam Hathi

By Patricia Spears

new guidelines will recommend that approximately thirteen million more Americans use cholesterol-reducing drugs. issued by the American heart Association, the new study was the product of a collaboration between researchers at Duke, Boston University and Mcgill University. The study examined previously available health data to determine the impact of the new guidelines, and found that the new guidelines would encourage nearly half the U.S. population between the ages of 40 and 75 to consider taking statins, which help lower cholesterol levels. This increase in the number of people who should take statins will occur because, for the first time, the guidelines will make recommendations based on an individual’s overall risk factors for heart disease instead of just their current cholesterol levels. “When the new guidelines came out, many experts gave educated guesses about what the impact might be,” said Michael Pencina, the study’s lead author and director of biostatistics at the Duke clinical research institute. “We don’t need to be

The number of veteran students at Duke has increased significantly over the last few years, but some say their veteran identity has not differentiated them from other average Duke students. There are currently 241 veteran students at Duke, said Associate Dean of Students clay Adams—compared to 35 in 2009, as reported by Duke Today. The majority of veteran students are enrolled in the Fuqua School of Business, and there are significantly more veteran graduate students than undergraduates. Although veterans say they are well-supported at Duke, they do not feel that their experience is significantly different from that of other students. “We’re here as students just like everyone else,” said luis Spradley, a firstyear MBA/MPP candidate who served as a security officer in the Marine corps for four years. “it’s an honor to be able to attend a school like Duke with our peers.” Both Spradley and Paul escajadillo—

The chronicle

The chronicle

AMANDA BRUMWELL/THE CHRONICLE

See GuiDeliNes, page 12

Matti Gorodenchik, an Israel Fellow from UF, gave an hour-long Krav Maga lesson Tuesday afternoon.

See VeTeraNs, page 4

duke scientists identify antibodies in HiV immune response By Shangnon Fei The chronicle

A research team led by Duke scientists has identified a subclass of antibodies that could help find an effective hiV vaccine. The study—published in the March 19 issue of Science Translational Medicine journal—looked at two hiV vaccine trials. The first, VAX003, involved one vaccine and was ineffective, but the second, rV144, involved two vaccines taken in combination and was effective. researchers found the difference between the two trials by

specifying a subclass of antibodies linked to hiV elimination and decreased risk of infection in rV144 vaccines. identifying this subclass of antibodies, called igg3, could help develop future vaccines, as well as enhance current understanding of immune response as it relates to hiV risk and prevention, said senior author georgia Tomaras, associate director of research at the Duke human Vaccine institute. “This is important because it shows that the antibody represents an effective immune response against the virus,” Tomaras

said. “So now we have a possible biomarker for scoring potential vaccine candidates, as in, we can now say that if a medicine elicits the igg3 response, it may be engaging a protective immune response.” The rationale that spurred this study was that both protective and non-protective vaccine regimens can give important insight into specific immune responses that are able to block hiV acquisition, Tomaras said. The second vaccine in rV144 is a boost of VAX003. This combination vaccine

had an unprecedented 31.2 percent efficacy rate at preventing hiV infection at 42 months after vaccination—though too low a rate to expand the use of the vaccine. “So the question is—why does rV144 have this vaccine efficacy, especially compared to the VAX003 trial, because they are using very much the same immunogens, but just in a different immunization regiment?” said DVhi research Director Dr. hua-Xin liao. “As scientists, we want to find out what the differences are and how See HiV, page 4


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.